BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37889272)

  • 1. Study of radiochemotherapy decision-making for young high-risk low-grade glioma patients using a macroscopic and microscopic combined radiomics model.
    Wu G; Shi Z; Li Z; Xie X; Tang Q; Zhu J; Yang Z; Wang Y; Wu J; Yu J
    Eur Radiol; 2024 May; 34(5):2861-2872. PubMed ID: 37889272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upfront Therapy of Aggressive/High-Risk Low-Grade Glioma: Single-Institution Outcome Analysis of Temozolomide-Based Radio-Chemotherapy and Adjuvant Chemotherapy.
    Anand S; Chatterjee A; Gupta T; Panda P; Moiyadi A; Epari S; Patil V; Krishnatry R; Goda JS; Jalali R
    World Neurosurg; 2021 Oct; 154():e176-e184. PubMed ID: 34245877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-sequence and habitat-based MRI radiomics signature for preoperative prediction of MGMT promoter methylation in astrocytomas with prognostic implication.
    Wei J; Yang G; Hao X; Gu D; Tan Y; Wang X; Dong D; Zhang S; Wang L; Zhang H; Tian J
    Eur Radiol; 2019 Feb; 29(2):877-888. PubMed ID: 30039219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
    Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
    Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase of pseudoprogression and other treatment related effects in low-grade glioma patients treated with proton radiation and temozolomide.
    Dworkin M; Mehan W; Niemierko A; Kamran SC; Lamba N; Dietrich J; Martinez-Lage M; Oh KS; Batchelor TT; Wen PY; Loeffler JS; Shih HA
    J Neurooncol; 2019 Mar; 142(1):69-77. PubMed ID: 30488294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
    Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
    Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiomics strategy for glioma grading using texture features from multiparametric MRI.
    Tian Q; Yan LF; Zhang X; Zhang X; Hu YC; Han Y; Liu ZC; Nan HY; Sun Q; Sun YZ; Yang Y; Yu Y; Zhang J; Hu B; Xiao G; Chen P; Tian S; Xu J; Wang W; Cui GB
    J Magn Reson Imaging; 2018 Dec; 48(6):1518-1528. PubMed ID: 29573085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting histological grade in pediatric glioma using multiparametric radiomics and conventional MRI features.
    Zhou T; Qiao B; Peng B; Liu Y; Gong Z; Kang M; He Y; Pang C; Dai Y; Sheng M
    Sci Rep; 2024 Jun; 14(1):13683. PubMed ID: 38871755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma.
    Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS
    Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.
    Steidl E; Filipski K; Zeiner PS; Wagner M; Fokas E; Forster MT; Ronellenfitsch MW; Divé I; Steinbach JP; Harter PN; Bähr O
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2373-2383. PubMed ID: 33538917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amide proton transfer-weighted imaging and derived radiomics in the classification of adult-type diffuse gliomas.
    Wu M; Jiang T; Guo M; Duan Y; Zhuo Z; Weng J; Xie C; Sun J; Li J; Cheng D; Liu X; Du J; Zhang X; Zhang Y; Liu Y
    Eur Radiol; 2024 May; 34(5):2986-2996. PubMed ID: 37855851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas.
    Han Y; Xie Z; Zang Y; Zhang S; Gu D; Zhou M; Gevaert O; Wei J; Li C; Chen H; Du J; Liu Z; Dong D; Tian J; Zhou D
    J Neurooncol; 2018 Nov; 140(2):297-306. PubMed ID: 30097822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033.
    Bady P; Kurscheid S; Delorenzi M; Gorlia T; van den Bent MJ; Hoang-Xuan K; Vauléon É; Gijtenbeek A; Enting R; Thiessen B; Chinot O; Dhermain F; Brandes AA; Reijneveld JC; Marosi C; Taphoorn MJB; Wick W; von Deimling A; French P; Stupp R; Baumert BG; Hegi ME
    Acta Neuropathol; 2018 Apr; 135(4):601-615. PubMed ID: 29368212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.
    McTyre E; Lucas JT; Helis C; Farris M; Soike M; Mott R; Laxton AW; Tatter SB; Lesser GJ; Strowd RE; Lo HW; Debinski W; Chan MD
    Am J Clin Oncol; 2018 Aug; 41(8):813-819. PubMed ID: 28301347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide in paediatric high-grade glioma: a key for combination therapy?
    Verschuur AC; Grill J; Lelouch-Tubiana A; Couanet D; Kalifa C; Vassal G
    Br J Cancer; 2004 Aug; 91(3):425-9. PubMed ID: 15266331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
    Cao M; Suo S; Zhang X; Wang X; Xu J; Yang W; Zhou Y
    Biomed Res Int; 2021; 2021():1235314. PubMed ID: 33553421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.